Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 514
Filter
1.
Iran J Med Sci ; 49(6): 359-368, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38952641

ABSTRACT

Background: Heart transplantation is the preferred treatment for end-stage heart failure. This study investigated the intra-operative risk factors affecting post-transplantation mortality. Methods: This single-center retrospective cohort study examined 239 heart transplant patients over eight years, from 2011-2019, at the oldest dedicated cardiovascular center, Shahid Rajaee Hospital (Tehran, Iran). The primary evaluated clinical outcomes were rejection, readmission, and mortality one month and one year after transplantation. For data analysis, univariate logistic regression analyses were conducted. Results: In this study, 107 patients (43.2%) were adults, and 132 patients (56.8%) were children. Notably, reoperation due to bleeding was a significant predictor of one-month mortality in both children (OR=7.47, P=0.006) and adults (OR=172.12, P<0.001). Moreover, the need for defibrillation significantly increased the risk of one-month mortality in both groups (children: OR=38.00, P<0.001; adults: OR=172.12, P<0.001). Interestingly, readmission had a protective effect against one-month mortality in both children (OR=0.02, P<0.001) and adults (OR=0.004, P<0.001). Regarding one-year mortality, the use of extracorporeal membrane oxygenation (ECMO) was associated with a higher risk in both children (OR=7.64, P=0.001) and adults (OR=12.10, P<0.001). For children, reoperation due to postoperative hemorrhage also increased the risk (OR=5.14, P=0.020), while defibrillation was a significant risk factor in both children and adults (children: OR=22.00, P<0.001; adults: OR=172.12, P<0.001). The median post-surgery survival was 22 months for children and 24 months for adults. Conclusion: There was no correlation between sex and poorer outcomes. Mortality at one month and one year after transplantation was associated with the following risk factors: the use of ECMO, reoperation for bleeding, defibrillation following cross-clamp removal, and Intensive Care Unit (ICU) stay. Readmission, on the other hand, had a weak protective effect.


Subject(s)
Heart Transplantation , Humans , Heart Transplantation/statistics & numerical data , Heart Transplantation/methods , Heart Transplantation/mortality , Heart Transplantation/adverse effects , Heart Transplantation/trends , Male , Female , Risk Factors , Retrospective Studies , Iran/epidemiology , Child , Adult , Middle Aged , Patient Readmission/statistics & numerical data , Adolescent , Child, Preschool , Reoperation/statistics & numerical data , Reoperation/mortality , Reoperation/methods , Young Adult , Postoperative Complications/mortality , Heart Failure/mortality , Heart Failure/surgery
2.
J Am Heart Assoc ; 13(13): e034055, 2024 Jul 02.
Article in English | MEDLINE | ID: mdl-38904229

ABSTRACT

BACKGROUND: Although peripartum cardiomyopathy (PPCM) is a fatal disease affecting young patients and fetuses, little is known about its recent prognosis and risk factors. This study investigated temporal trends in clinical characteristics and outcomes for PPCM in a nationwide multicenter registry. METHODS AND RESULTS: The study population comprised 340 patients (mean age, 33 years) who were diagnosed with PPCM between January 2000 and September 2022 in 26 tertiary hospitals in South Korea. PPCM was defined as heart failure with left ventricular ejection fraction ≤45% and no previously known cardiac disease. The main study outcomes included time to the first occurrence of all-cause death, heart transplantation, and cardiovascular hospitalization. The diagnosis of PPCM cases increased notably during the study period (P<0.001). However, clinical outcomes showed no significant improvement (all-cause death for 10 years: 0.9% [2000-2010] versus 2.3% [2011-2022], P=0.450; all-cause death and heart transplantation for 10 years: 3.6% [2000-2010] versus 3.0% [2011-2022] P=0.520; all-cause death, heart transplantation, and cardiovascular hospitalization for 10 years: 11.7% [2000-2010] versus 19.8% [2011-2022], P=0.240). High body mass index (hazard ratio [HR], 1.106 [95% CI, 1.024-1.196]; P=0.011), the presence of gestational diabetes (HR, 5.346 [95% CI, 1.778-16.07]; P=0.002), and increased baseline left ventricular end-diastolic dimension (HR, 1.078 [95% CI, 1.002-1.159]; P=0.044) were significant risk factors for poor prognosis. CONCLUSIONS: While the incidence of PPCM has increased over the past 20 years, the prognosis has not improved significantly. Timely management and close follow-up are necessary for high-risk patients with PPCM with high body mass index, gestational diabetes, or large left ventricular end-diastolic dimension.


Subject(s)
Cardiomyopathies , Peripartum Period , Pregnancy Complications, Cardiovascular , Registries , Humans , Female , Adult , Pregnancy , Republic of Korea/epidemiology , Cardiomyopathies/epidemiology , Cardiomyopathies/therapy , Cardiomyopathies/physiopathology , Cardiomyopathies/mortality , Pregnancy Complications, Cardiovascular/epidemiology , Pregnancy Complications, Cardiovascular/therapy , Risk Factors , Time Factors , Heart Transplantation/trends , Heart Transplantation/statistics & numerical data , Prognosis , Ventricular Function, Left , Stroke Volume , Cause of Death/trends , Hospitalization/trends , Hospitalization/statistics & numerical data , Puerperal Disorders/epidemiology , Puerperal Disorders/therapy , Puerperal Disorders/mortality , Puerperal Disorders/physiopathology , Retrospective Studies , Heart Failure/epidemiology , Heart Failure/mortality , Heart Failure/therapy , Heart Failure/physiopathology , Incidence
4.
J Cardiothorac Vasc Anesth ; 38(7): 1514-1523, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38664136

ABSTRACT

OBJECTIVES: This study aimed to identify perioperative risk factors of acute kidney injury after heart transplantation and to evaluate 1-year clinical outcomes. DESIGN: A retrospective single-center cohort study. SETTING: At a university hospital. PARTICIPANTS: All patients who underwent heart transplantation from January 2015 to December 2020. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The authors recorded acute kidney injury after heart transplantation. One-year mortality and renal function also were recorded. Risk factors of acute kidney injury were evaluated using a multivariate logistic regression model. Long-term survival was compared between patients developing acute kidney injury and those who did not, using a log-rank test. Among 209 patients included in this study, 134 patients (64% [95% CI (58; 71)]) developed posttransplantation acute kidney injury. Factors independently associated with acute kidney injury were high body mass index (odds ratio [OR]: 1.18 [1.02-1.38] per kg/m2; p = 0.030), prolonged duration of cold ischemic period (OR: 1.11 [1.01-1.24] per 10 minutes; p = 0.039), and high dose of intraoperative dobutamine support (OR: 1.24 [1.06-1.46] per µg/kg/min; p = 0.008). At 1 year, patients who developed postoperative acute kidney injury had higher mortality rates (20% v 8%, p = 0.015). Among 172 survivors at 1 year, 82 survivors (48%) had worsened their renal function compared with preheart transplantation. CONCLUSIONS: This study highlighted the high incidence of acute kidney injury after heart transplantation and its impact on patient outcomes. Risk factors such as body mass index, prolonged cold ischemic period duration, and level of inotropic support with dobutamine were identified, providing insights for preventive strategies.


Subject(s)
Acute Kidney Injury , Heart Transplantation , Postoperative Complications , Humans , Retrospective Studies , Acute Kidney Injury/epidemiology , Acute Kidney Injury/etiology , Male , Female , Heart Transplantation/adverse effects , Heart Transplantation/trends , Middle Aged , Risk Factors , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Adult , Cohort Studies , Time Factors , Follow-Up Studies
5.
J Heart Lung Transplant ; 43(6): 863-865, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38368912

ABSTRACT

Heart valve replacement in children is an unsolved problem in congenital cardiac surgery because state-of-the-art heart valve implants do not grow. This leads to serial repeat operations to replace outgrown heart valve implants. Partial heart transplantation is a new transplant that helps alleviate this problem by delivering growing heart valve implants. In the future, partial heart transplantation has the potential to complement conventional heart transplantation for treating children with congenital cardiac disease primarily affecting the heart valves.


Subject(s)
Heart Transplantation , Humans , Heart Transplantation/methods , Heart Transplantation/trends , Child , Heart Defects, Congenital/surgery , Heart Valve Prosthesis , Forecasting , Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis Implantation/trends
7.
JAMA ; 328(20): 1999-2001, 2022 11 22.
Article in English | MEDLINE | ID: mdl-36322069

ABSTRACT

This Medical News article discusses how cardiac xenotransplantation with genetically modified pig hearts might help relieve the shortage of human donor hearts.


Subject(s)
Heart Transplantation , Transplantation, Heterologous , Animals , Humans , Animals, Genetically Modified , Graft Survival , Heart Transplantation/trends , Swine , Transplantation, Heterologous/trends , Forecasting
9.
Pediatrics ; 149(2)2022 02 01.
Article in English | MEDLINE | ID: mdl-35079811

ABSTRACT

OBJECTIVES: Progress in pediatric transplantation measured in the context of waitlist and posttransplant survival is well documented but falls short of providing a complete perspective for children and their families. An intent-to-treat analysis, in which we measure survival from listing to death regardless of whether a transplant is received, provides a more comprehensive perspective through which progress can be examined. METHODS: Univariable and multivariable Cox regression was used to analyze factors impacting intent-to-treat survival in 12 984 children listed for heart transplant, 17 519 children listed for liver transplant, and 16 699 children listed for kidney transplant. The Kaplan-Meier method and log-rank test were used to assess change in waitlist, posttransplant, and intent-to-treat survival. Wait times and transplant rates were compared by using χ2 tests. RESULTS: Intent-to-treat survival steadily improved from 1987 to 2017 in children listed for heart (hazard ratio [HR] 0.96, 95% confidence interval [CI] 0.96-0.97), liver (HR 0.95, 95% CI 0.94-0.97), and kidney (HR 0.97, 95% CI 0.95-0.99) transplant. Waitlist and posttransplant survival also improved steadily for all 3 organs. For heart transplant, the percentage of patients transplanted within 1 year significantly increased from 1987 to 2017 (60.8% vs 68.7%); however, no significant increase was observed in liver (68.9% vs 72.5%) or kidney (59.2% vs 62.7%) transplant. CONCLUSIONS: Intent-to-treat survival, which is more representative of the patient perspective than individual metrics alone, steadily improved for heart, liver, and kidney transplant over the study period. Further efforts to maximize the donor pool, improve posttransplant outcomes, and optimize patient care while on the waitlist may contribute to future progress.


Subject(s)
Heart Transplantation/mortality , Heart Transplantation/trends , Kidney Transplantation/mortality , Kidney Transplantation/trends , Liver Transplantation/mortality , Liver Transplantation/trends , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Male , Retrospective Studies , Survival Rate/trends , Tissue Donors/supply & distribution , Tissue and Organ Procurement/methods , Tissue and Organ Procurement/trends , Waiting Lists/mortality
10.
J Am Heart Assoc ; 10(24): e023662, 2021 12 21.
Article in English | MEDLINE | ID: mdl-34743559

ABSTRACT

Background Because of discrepancies between donor supply and recipient demand, the cardiac transplantation process aims to prioritize the most medically urgent patients. It remains unknown how recipients with the lowest medical urgency compare to others in the allocation process. We aimed to examine differences in clinical characteristics, organ allocation patterns, and outcomes between cardiac transplantation candidates with the lowest and highest medical urgency. Methods and Results We performed a retrospective analysis of the United Network for Organ Sharing database. Patients listed for cardiac transplantation between January 2011 and May 2020 were stratified according to status at time of transplantation. Baseline recipient and donor characteristics, waitlist survival, and posttransplantation outcomes were compared in the years before and after the 2018 allocation system change. Lower urgency patients in the old system were older (58.5 versus 56 years) and more likely female (54.4% versus 23.8%) compared with the highest urgency patients, and these trends persisted in the new system (P<0.001, all). Donors for the lowest urgency patients were more likely older, female, or have a history of cytomegalovirus, hepatitis C, or diabetes (P<0.01, all). The lowest urgency patients had longer waitlist times and under the new allocation system received organs from shorter distances with decreased ischemic times (178 miles versus 269 miles, 3.1 versus 3.5 hours; P<0.001, all). There was no difference in posttransplantation survival (P<0.01, all). Conclusions Patients transplanted as lower urgency receive hearts from donors with additional comorbidities compared with higher urgency patients, but outcomes are similar at 1 year.


Subject(s)
Heart Transplantation , Databases, Factual , Female , Heart Transplantation/trends , Humans , Male , Retrospective Studies , Survival Analysis , Tissue Donors/statistics & numerical data , Tissue Donors/supply & distribution , Treatment Outcome , Waiting Lists
11.
Curr Med Sci ; 41(5): 841-846, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34652629

ABSTRACT

The purpose of this review is to provide a comprehensive update on recent advances in heart transplantation in China. Despite advances in pharmacologic and device treatment of chronic heart failure, long-term morbidity and mortality remain high, and many patients progress to endstage heart failure. Heart transplantation has become standard treatment for selected patients with end-stage heart failure, though challenges still exist. However, multiple advances over the past few years will improve the survival and quality-of-life of heart transplant recipients. This article elaborates on the specific characteristics of heart transplantation in China, the current issues, development trends, and related experiences with heart transplantation in Wuhan Union Hospital.


Subject(s)
Heart Failure/therapy , Heart Transplantation/trends , China , Humans , Quality of Life , Standard of Care
13.
J Am Heart Assoc ; 10(15): e019655, 2021 08 03.
Article in English | MEDLINE | ID: mdl-34315285

ABSTRACT

Background It is unclear whether the recent increase in the number of heart transplants performed annually in the United States is only because of higher availability of donors and if it affected recipients' survival. Methods and Results We examined characteristics of donors and recipients from 2008 to 2012 (n=11 654) and 2013 to 2017 (n=14 556) and compared them with 2003 to 2007 (n=10 869). Cox models examined 30-day and 1-year risk of recipients' death post transplant. From 2013 to 2017, there was an increase in the number of transplanted hearts and number of donor offers but an overall decline in the ratio of hearts transplanted to available donors. Donors between 2013 and 2017 were older, heavier, more hypertensive, diabetic, and likely to have abused illicit drugs compared with previous years. Drug overdose and hepatitis C positive donors were additional contributors to donor risk in recent years. In Cox models, risk of death post transplant between 2013 and 2017 was 15% lower at 30 days (hazard ratio [HR] 0.85; 95% CI, 0.74-0.98) and 21% lower at 1 year (HR, 0.79; 95% CI, 0.73-0.87) and between 2008 and 2012 was 9% lower at 30 days (HR, 0.91; 95% CI, 0.79-1.05) and 14% lower at 1 year (HR, 0.86; 95% CI, 0.79-0.94) compared with 2003 to 2007. Conclusions Despite a substantial increase in heart donor offers in recent years, the ratio of transplants performed to available donors has decreased. Even though hearts from donors who are older, more hypertensive, and have diabetes mellitus are being used, overall recipient survival continues to improve. Broader acceptance of drug overdose and hepatitis C positive donors may increase the number and percentage of heart transplants further without jeopardizing short-term outcomes.


Subject(s)
Donor Selection/trends , Heart Failure/surgery , Heart Transplantation/trends , Tissue Donors/supply & distribution , Adolescent , Adult , Cause of Death/trends , Child , Child, Preschool , Databases, Factual , Drug Overdose/mortality , Female , Heart Failure/diagnosis , Heart Failure/mortality , Heart Transplantation/adverse effects , Heart Transplantation/mortality , Hepatitis C/diagnosis , Humans , Infant , Infant, Newborn , Male , Middle Aged , Patient Safety , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome , United States , Young Adult
14.
J Clin Lipidol ; 15(4): 579-583, 2021.
Article in English | MEDLINE | ID: mdl-34120877

ABSTRACT

Although statin therapy is a primary treatment to prevent cardiac allograft vasculopathy (CAV), its use may be delayed due to pharmacologic interactions in the early post-transplant period among heart transplant (HT) recipients with hepatitis C virus positive (HCV+) donors. Further examination of the possible benefits of early, nonstatin lipid-lowering therapies (LLT), such as PCSK9 inhibitors (PCSK9i), among this specific subset of transplant recipients is therefore becoming increasingly important. We report a 60-year-old man who received a HT from a HCV+ donor for end-stage ischemic cardiomyopathy. In the early post-transplant period, there was concern for drug-drug interactions between statin, immunosuppressant, and direct acting antiviral (DAA) therapy. In addition, prior to transplant, he reported statin-associated muscle symptoms in response to multiple statins, which persisted despite attempts to re-challenge and use an every-other-day dosing strategy. Therefore, the patient was started on PCSK9i therapy after transplantation and while receiving curative DAA therapy for HCV. As the number of HT recipients of HCV+ donors continue to rise, investigation into the safety and benefits of early use of PCSK9i for the reduction of CAV and improved cardiovascular and mortality outcomes should be pursued.


Subject(s)
Graft Rejection/drug therapy , Heart Transplantation/trends , Hepatitis C/drug therapy , Living Donors , PCSK9 Inhibitors/administration & dosage , Proprotein Convertase 9/metabolism , Graft Rejection/diagnosis , Graft Rejection/immunology , Hepatitis C/diagnosis , Hepatitis C/immunology , Humans , Male , Middle Aged
15.
BMC Cardiovasc Disord ; 21(1): 307, 2021 06 18.
Article in English | MEDLINE | ID: mdl-34144681

ABSTRACT

BACKGROUND: Temporal trends in clinical composition and outcome in dilated cardiomyopathy (DCM) are largely unknown, despite considerable advances in heart failure management. We set out to study clinical characteristics and prognosis over time in DCM in Sweden during 2003-2015. METHODS: DCM patients (n = 7873) from the Swedish Heart Failure Registry were divided into three calendar periods of inclusion, 2003-2007 (Period 1, n = 2029), 2008-2011 (Period 2, n = 3363), 2012-2015 (Period 3, n = 2481). The primary outcome was the composite of all-cause death, transplantation and hospitalization during 1 year after inclusion into the registry. RESULTS: Over the three calendar periods patients were older (p = 0.022), the proportion of females increased (mean 22.5%, 26.4%, 27.6%, p = 0.0001), left ventricular ejection fraction was higher (p = 0.0014), and symptoms by New York Heart Association less severe (p < 0.0001). Device (implantable cardioverter defibrillator and/or cardiac resynchronization) therapy increased by 30% over time (mean 11.6%, 12.3%, 15.1%, p < 0.0001). The event rates for mortality, and hospitalization were consistently decreasing over calendar periods (p < 0.0001 for all), whereas transplantation rate was stable. More advanced physical symptoms correlated with an increased risk of a composite outcome over time (p = 0.0043). CONCLUSIONS: From 2003 until 2015, we observed declining mortality and hospitalizations in DCM, paralleled by a continuous change in both demographic profile and therapy in the DCM population in Sweden, towards a less affected phenotype.


Subject(s)
Cardiac Resynchronization Therapy/trends , Cardiomyopathy, Dilated/therapy , Cardiovascular Agents/therapeutic use , Electric Countershock/trends , Heart Transplantation/trends , Hospitalization/trends , Aged , Cardiac Resynchronization Therapy/adverse effects , Cardiac Resynchronization Therapy/mortality , Cardiomyopathy, Dilated/diagnosis , Cardiomyopathy, Dilated/mortality , Cardiomyopathy, Dilated/physiopathology , Cardiovascular Agents/adverse effects , Cause of Death/trends , Disease Progression , Electric Countershock/adverse effects , Electric Countershock/mortality , Female , Heart Transplantation/adverse effects , Heart Transplantation/mortality , Humans , Male , Middle Aged , Phenotype , Prognosis , Registries , Risk Factors , Sweden , Time Factors
17.
Hepatology ; 73(4): 1464-1477, 2021 04.
Article in English | MEDLINE | ID: mdl-32559317

ABSTRACT

BACKGROUND AND AIMS: There are more adults than children living with congenital heart disease (CHD) in the United States, with a growing proportion requiring heart-liver transplantation (HLT). Our aim was to ascertain the frequency, outcomes, and prognostic factors in this patient population. APPROACH AND RESULTS: United Network for Organ Sharing data on adult patients who underwent heart transplantation (HT) from 2009 through March 2020 were analyzed. The primary study outcome was patient survival. Cox proportional-hazards modeling assessed for mortality associations. There were 1,084 HT recipients: 817 (75.4%) CHD HTs only, 74 (6.8%) CHD HLTs, 179 (16.5%) non-CHD HLTs, and 14 (1.3%) heart-liver-kidney transplants. The number of CHD HLTs increased from a prior rate of 4/year to 21/year in 2019. Among patients with CHD, the 5-year survival rates were 74.1% and 73.6% in HTs only and HLTs, respectively (P = 0.865). There was a higher rate of allograft failure attributable to rejection in CHD HTs only compared with CHD HLTs (3.2% versus 0.4%; P = 0.014). Only 25 out of 115 HT-performing hospitals undertook CHD HLTs. Higher-volume centers (averaging one CHD HLT per year) had a 5-year patient survival rate of 83.0% compared with 61.3% in lower-volume centers (P = 0.079). Among HLT recipients, total bilirubin (hazard ratio [HR], 1.06; 95% confidence interval [CI], 1.01-1.12) and diabetes (HR = 2.97, 95% CI = 1.21-7.31) were independently associated with increased mortality risk, whereas CHD and age were not. CONCLUSIONS: The rate of HLT for adult CHD in the United States is rising dramatically. The survival outcomes between CHD HT only and CHD HLT groups are comparable; however, the HLT group had lower rates of acute rejection. Among HLT recipients, diabetes and elevated bilirubin are associated with increased posttransplant mortality risk. An average of one CHD HLT per year could be considered a minimum quality metric at transplant centers.


Subject(s)
Heart Defects, Congenital/surgery , Heart Transplantation/mortality , Heart Transplantation/methods , Liver Transplantation/mortality , Liver Transplantation/methods , Outcome Assessment, Health Care , Adult , Bilirubin/blood , Diabetes Complications/mortality , Female , Follow-Up Studies , Heart Defects, Congenital/blood , Heart Defects, Congenital/epidemiology , Heart Transplantation/trends , Humans , Liver Transplantation/trends , Male , Middle Aged , Prognosis , Prospective Studies , Survival Rate , Tissue Donors , Transplant Recipients , Transplantation, Homologous/methods , Transplantation, Homologous/mortality , Transplantation, Homologous/trends , United States/epidemiology , Young Adult
18.
Interact Cardiovasc Thorac Surg ; 32(3): 476-482, 2021 04 08.
Article in English | MEDLINE | ID: mdl-33221874

ABSTRACT

OBJECTIVES: Patients with mechanical circulatory support bridged to a heart transplant (HTx) are at higher risk of postoperative graft dysfunction. In this subset, a mode of graft preservation that shortens graft ischaemia should be beneficial. METHODS: The outcomes of 38 patients on mechanical circulatory support (extracorporeal life support, left ventricular assist device and biventricular assist device) who received a HTx between 2015 and 2020 were analysed according to the method of graft preservation: cold storage (CS) group, 24 (63%) or ex vivo perfusion (EVP) group, 14 (37%). RESULTS: The median age was 57 (range 30-73) vs 64 (35-75) years (P = 0.10); 88% were men (P = 0.28); extracorporeal life support was more frequent in the CS group (54% vs 36%; P = 0.27) versus left ventricular and biventricular assist devices in the EVP group (46% vs 64%; P = 0.27). Clamping time was shorter in the EVP group (P < 0.001) and ischaemic time >4 h was higher in the CS group (P = 0.01). Thirty-day mortality was 13% (0-27%) in the CS group and 0% (P = 0.28) in the EVP group. A significantly lower primary graft failure [7% (0-23%) vs 42% (20-63%); P = 0.03] was observed in the EVP group. Survival at 1 year was 79 ± 8% (63-95%) in the CS group and 84 ± 10% (64-104%) in the EVP group (P = 0.95). CONCLUSIONS: Our results support the use of ex vivo graft perfusion in patients on mechanical circulatory support as a bridge to a HTx. This technique, by shortening graft ischaemic time, seems to improve post-HTx outcomes.


Subject(s)
Cryopreservation/methods , Extracorporeal Membrane Oxygenation/methods , Heart Transplantation/methods , Organ Preservation/methods , Perfusion/methods , Adult , Aged , Extracorporeal Circulation/methods , Extracorporeal Circulation/trends , Extracorporeal Membrane Oxygenation/trends , Female , Follow-Up Studies , Heart Transplantation/trends , Heart-Assist Devices/trends , Humans , Male , Middle Aged , Organ Preservation/trends , Perfusion/trends , Retrospective Studies , Treatment Outcome
19.
J Heart Lung Transplant ; 40(1): 69-86, 2021 01.
Article in English | MEDLINE | ID: mdl-33162304

ABSTRACT

Despite the advancements in medical treatment, mechanical support, and stem cell therapy, heart transplantation remains the most effective treatment for selected patients with advanced heart failure. However, with an increase in heart failure prevalence worldwide, the gap between donor hearts and patients on the transplant waiting list keeps widening. Ex situ machine perfusion has played a key role in augmenting heart transplant activities in recent years by enabling the usage of donation after circulatory death hearts, allowing longer interval between procurement and implantation, and permitting the safe use of some extended-criteria donation after brainstem death hearts. This exciting field is at a hinge point, with 1 commercially available heart perfusion machine, which has been used in hundreds of heart transplantations, and a number of devices being tested in the pre-clinical and Phase 1 clinical trial stage. However, no consensus has been reached over the optimal preservation temperature, perfusate composition, and perfusion parameters. In addition, there is a lack of objective measurement for allograft quality and viability. This review aims to comprehensively summarize the lessons about ex situ heart perfusion as a platform to preserve, assess, and repair donor hearts, which we have learned from the pre-clinical studies and clinical applications, and explore its exciting potential of revolutionizing heart transplantation.


Subject(s)
Heart Transplantation/trends , Organ Preservation/trends , Perfusion/trends , Tissue Donors , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...